About
Open-angle Glaucoma Treatment
Tisbury Pharmaceuticals is a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of treatments for primary open-angle glaucoma. The company's clinical candidate, R-801, accelerates flow through the trabecular meshwork via redox catalysis and K+-ATP channel activation.
Identity
| Name | Tisbury Pharmaceuticals |
|---|---|
| Slug | tisbury-pharmaceuticals |
| Type / kind | startup |
| Crunchbase ID | tisbury-pharmaceuticals |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNeI_ZwKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Nov 2019 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Qatsrin |
| HQ address | Qatsrin |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pharmaceuticalseye-diseasesdrug-discoveryglaucoma
Funding
| Total raised | $32.0M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}